At the investor day they mentioned that about two thirds of practices cover neuromodulators by category (i.e. no preference for a brand), and 30% require you to use a specific brand (and if any contraindication or lack of effect then can step up to another bont). I think given the advantageous economics of daxi they are likely to move to be the preferred bont for CD, but they probably won't get coverage for off label use as much w these plans because they are dictating the specific preferred toxin. for the former they have to compete more for the CD market, but if they get lumped in with other toxins I think some payers will cover daxi for other uses as long as there is some supportive data, and there is a phase 2 in upper limb with data. I also think there will be investigator sponsored studies in other indications over time even if RVNC doesn't have the money yet to run trials in other therapeutic indications. this could provide a larger body of data for other off label uses in time.
Market Data 
Markets 
AI
